"{\"id\":\"19e835652de845068ac749b622e108a3\",\"object\":\"chat.completion\",\"model\":\"mistral-small-latest\",\"usage\":{\"prompt_tokens\":6688,\"completion_tokens\":1078,\"total_tokens\":7766},\"created\":1749773796,\"choices\":[{\"index\":0,\"message\":{\"content\":\"Here is the extracted information from the document, formatted as JSON for easy reference and future use:\\n\\n```json\\n{\\n  \\\"form_name\\\": \\\"Antimigraine Agents, Vyepti (Eptinezumab-jmmr) Prior Authorization (PA) Form\\\",\\n  \\\"provider\\\": \\\"HealthKeepers, Inc. | Anthem HealthKeepers Plus Medicaid products\\\",\\n  \\\"instructions\\\": \\\"If the following information is not complete, correct, or legible, the PA process can be delayed. Please use one form per member.\\\",\\n  \\\"sections\\\": {\\n    \\\"member_information\\\": {\\n      \\\"last_name\\\": \\\"Chen\\\",\\n      \\\"first_name\\\": \\\"Amy\\\",\\n      \\\"medicaid_id_number\\\": \\\"\\\",\\n      \\\"date_of_birth\\\": \\\"05/23/1983\\\",\\n      \\\"weight_in_kilograms\\\": \\\"50.9\\\"\\n    },\\n    \\\"prescriber_information\\\": {\\n      \\\"last_name\\\": \\\"Nicole\\\",\\n      \\\"first_name\\\": \\\"Angela\\\",\\n      \\\"npi_number\\\": \\\"\\\",\\n      \\\"phone_number\\\": \\\"421-771-9001\\\",\\n      \\\"fax_number\\\": \\\"421-771-843\\\"\\n    },\\n    \\\"drug_information\\\": {\\n      \\\"drug_name\\\": \\\"Vyepti (Eptinezumab-jmmr)\\\",\\n      \\\"drug_strength\\\": \\\"100 mg/mL\\\",\\n      \\\"length_of_therapy\\\": \\\"\\\",\\n      \\\"drug_form\\\": \\\"solution\\\",\\n      \\\"dosing_frequency\\\": \\\"once every 3 months\\\",\\n      \\\"quantity\\\": \\\"1 mL\\\"\\n    },\\n    \\\"drug_information_continued\\\": {\\n      \\\"member_last_name\\\": \\\"Chen\\\",\\n      \\\"member_first_name\\\": \\\"Amy\\\",\\n      \\\"preventive_treatment\\\": {\\n        \\\"preferred_agents\\\": [\\n          \\\"Aimovig\\\",\\n          \\\"Ajovy and Ajovy autoinjector\\\",\\n          \\\"Emgality pen and syringe (120 mg)\\\",\\n          \\\"Nurtec ODT\\\"\\n        ],\\n        \\\"non_preferred_agents\\\": [\\n          \\\"Emgality syringe (100 mg)\\\",\\n          \\\"Qulipta\\\",\\n          \\\"Vyepti\\\"\\n        ]\\n      },\\n      \\\"acute_treatment\\\": {\\n        \\\"preferred_agents\\\": [\\n          \\\"Nurtec ODT\\\",\\n          \\\"Ubrelvy\\\"\\n        ],\\n        \\\"non_preferred_agents\\\": [\\n          \\\"Reyvow\\\",\\n          \\\"Trudhesa\\\",\\n          \\\"Zavzpret\\\"\\n        ]\\n      },\\n      \\\"preferred_agents_cannot_be_used\\\": \\\"The patient has tried multiple medications and prefers Vyepti over Botox.\\\"\\n    },\\n    \\\"drug_information_questions\\\": {\\n      \\\"question_1\\\": {\\n        \\\"text\\\": \\\"Does the member have a diagnosis of migraine with or without aura based on International Classification of Headache Disorders (ICHD-III) diagnostic criteria?\\\",\\n        \\\"options\\\": [\\\"Yes\\\"]\\n      },\\n      \\\"question_2\\\": {\\n        \\\"text\\\": \\\"Is the member \u2265 18 years of age?\\\",\\n        \\\"options\\\": [\\\"Yes\\\"]\\n      },\\n      \\\"question_3\\\": {\\n        \\\"text\\\": \\\"Has the member been utilizing prophylactic intervention modalities (for example, pharmacotherapy, behavioral therapy, physical therapy, etc.)?\\\",\\n        \\\"options\\\": [\\\"Yes\\\"]\\n      },\\n      \\\"question_4\\\": {\\n        \\\"text\\\": \\\"Does the member have a diagnosis of chronic migraines defined as 15 or more headache (tension-type-like and/or migraine-like) days per month for > three months?\\\",\\n        \\\"sub_questions\\\": [\\n          {\\n            \\\"text\\\": \\\"Member has had at least five attacks with features consistent with migraine (with and/or without aura);\\\",\\n            \\\"options\\\": [\\\"Yes\\\"]\\n          },\\n          {\\n            \\\"text\\\": \\\"On at least eight days per month for > three months:\\\",\\n            \\\"sub_questions\\\": [\\n              {\\n                \\\"text\\\": \\\"Headaches have characteristics and symptoms consistent with migraine;\\\",\\n                \\\"options\\\": [\\\"Yes\\\"]\\n              },\\n              {\\n                \\\"text\\\": \\\"Member suspected migraines are relieved by a triptan or ergot derivative medication;\\\",\\n                \\\"options\\\": [\\\"Yes\\\"]\\n              }\\n            ]\\n          },\\n          {\\n            \\\"text\\\": \\\"Member has failed at least an eight-week trial of any two oral medications for the prevention of migraines (for example, antidepressants, beta blockers, antiepileptics) prior to initiation of eptinezumab;\\\",\\n            \\\"options\\\": [\\\"Yes\\\"]\\n          },\\n          {\\n            \\\"text\\\": \\\"Member had an inadequate response (or unable to tolerate) a minimum trial of at least two preferred self-injectable CGRP options;\\\",\\n            \\\"options\\\": [\\\"Yes\\\"]\\n          }\\n        ]\\n      }\\n    }\\n  },\\n  \\\"left_blank\\\": [\\n    \\\"The NPI number in the prescriber information section.\\\",\\n    \\\"The Medicaid ID number in the member information section.\\\",\\n    \\\"The length of therapy in the drug information section.\\\",\\n    \\\"The address, city, state, and zipcode in the demographics section.\\\"\\n  ]\\n}\\n```\\n\\nThis JSON structure can be used to extract and reference the information from a larger document in the future.\",\"tool_calls\":null,\"prefix\":false,\"role\":\"assistant\"},\"finish_reason\":\"stop\"}]}"